Figure 6.
Erlotinib does not reduce PDT selectivity. Tumor size (pre-PDT) and scab size after treatment with PDT or erlotinib/PDT was quantified by in vivo imaging (n=4–11). *p<0.05 for comparison to pre-PDT tumor size of the respective group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.